Conversely, both c‐Myc‐i7 (IC50 of 81.7 μM) and c‐Myc‐i8 (89.4 μM) displayed reduced effectiveness in treating pancreatic cancer when compared to 10058‐F4. This evidence concerns the gene MYC and pancreatic neoplasm.